- Avid Bioservices Inc (NASDAQ:CDMO) reported Q4 FY22 sales of $31.2 million, up 13% Y/Y, beating the consensus of $28.96 million.
- The growth is attributed to an increase in the scope of in-process and completed manufacturing runs and process development revenues.
- The company signed multiple new project orders during Q4 totaling approximately $44 million.
- For FY22, the company signed net new project orders for $155 million, leading to a backlog of $153 million (+30%), Avid's largest backlog to date.
- Q4 gross margin was 22%, down from 29% a year ago, primarily from increases in costs partially offset by higher revenues.
- Avid Bioservices posted a Q4 EPS of $1.65, a shift from an EPS loss of $(0.04) a year ago.
- The company reported $126.2 million in cash and cash equivalents.
- Guidance: Avid Bioservices expects FY23 sales of $140 million - $145 million, a 17% - 21% increase over FY22, compared to the consensus of $146.5 million.
- Price Action: CDMO shares closed 5.47% higher at $16.00 during after-hours trading on Wednesday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
Read How Avid Bioservices Fared In Q4
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks